Table 1.
Population demographics
| All | AL | TTR | Other | |
| n=50 | n=31 | n=17 | n=2 | |
| Age, years | 68±11 | 65±10 | 77±9 | 58±4 |
| Men, n (%) | 37 (74) | 19 (61) | 16 (94) | 0 |
| Weight, kg | 73±13 | 74±14 | 74±9 | 49±10 |
| Height, m | 1.69±0.08 | 1.69±0.08 | 1.71±0.06 | 1.56±0.09 |
| Body mass index, kg/m2 | 26±4 | 26±4 | 25±3 | 20±2 |
| Diabetes mellitus, n (%) | 6 (13) | 3 (10) | 3 (18) | 0 |
| Hypertension, n (%) | 23 (48) | 13 (42) | 9 (53) | 2 (100) |
| Hypercholesterolaemia, n (%) | 13 (27) | 7 (23) | 6 (35) | 0 |
| Smoking, n (%) | 5 (10) | 5 (10) | 0 | 0 |
| NYHA stage, n (%) | 48 (96) | 29 (94) | 16 (94) | 2 (100) |
| I | 1 (2) | 0 | 1 (6) | 0 |
| II | 21 (42) | 12 (39) | 7 (41) | 2 (100) |
| III | 21 (42) | 13 (42) | 8 (47) | 0 |
| IV | 4 (8) | 4 (13) | 0 | 0 |
| Systolic blood pressure, mm Hg | 118±20 | 112±17 | 128±16 | 120±28 |
| Diastolic blood pressure, mm Hg | 69±11 | 69±8 | 70±8 | 80±14 |
| Heart rate (beats/min) | 77±16 | 84±10 | 65±10 | 81±1 |
| Pacemaker, n (%) | 10 (20) | 3 (10) | 7 (41) | 0 |
| Atrial fibrillation, n (%) | 21 (44) | 10 (33) | 10 (59) | 1 (50) |
| Medication at inclusion | ||||
| ACEI/ARB, n (%) | 17 (35) | 11 (35) | 7 (42) | 1 (50) |
| Furosemide, n (%) | 43 (86) | 27 (87) | 16 (94) | 0 |
| Posology (mg/day) | 226 (80–250) | 243 (80–250) | 197 (80–229) | 0 |
| Mean eGFR (mL/min), n (%) | 46±21 | 48±30 | 44±18 | 38±30 |
| eGFR <30 mL/min | 13 (26) | 6 (19) | 6 (35) | 1 (50) |
| 30≤ eGFR <45 mL/min | 12 (24) | 9 (29) | 4 (23) | 0 |
| 45≤ eGFR <60 mL/min | 9 (18) | 5 (16) | 3 (18) | 0 |
| eGFR ≥60 mL/min | 16 (32) | 11 (35) | 4 (23) | 1 (50) |
ACEI, ACE inhibitor;AL, light chains amyloidosis; ARB, angiotensin II receptor antagonist;eGFR, estimated glomerular filtration rate;NYHA, New York Heart Association; TTR, transthyretin amyloidosis.